---
schema_version: "secwatch.filing_event.v1"
accession: "0001174947-25-001185"
form_type: "8-K"
ticker: "CNMD"
cik: "0000816956"
company_name: "CONMED Corp"
filed_at: "2025-09-09T23:59:59+00:00"
generated_at: "2026-05-17T07:25:36.290577+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# CONMED appoints Kim Kelderman to Board of Directors effective Sept 8, 2025

## Summary
- Kim Kelderman appointed to CONMED's Board, effective September 8, 2025.
- He serves on Corporate Governance & Nominating and Strategy Committees.
- Kelderman is President & CEO of Bio-Techne (TECH) since February 2024.
- Granted prorated equity valued at ~$134,766 (500 RSUs + options for 6,227 shares).
- Prior roles include Thermo Fisher Scientific and Becton Dickinson.

## SEC filing metadata
- accession: 0001174947-25-001185
- form_type: 8-K
- ticker: CNMD
- cik: 0000816956
- company_name: CONMED Corp
- filed_at: 2025-09-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/816956/000117494725001185/0001174947-25-001185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/816956/000117494725001185/form8k-34670_cnmd.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001174947-25-001185
- JSON: https://secwatch.observer/filing/0001174947-25-001185.json
- Plain text: https://secwatch.observer/filing/0001174947-25-001185.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.